|
FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”), a global medical provider of electrocardiogram ("ECG") acquisition and management software solutions, announces the HeartCheck™ ECG PEN is now available on the shelves of select Rexall Pharmacies in Canada.
Participating Rexall Pharmacies will display the HeartCheck™ ECG PEN in their diabetes over-the-counter (OTC) section. In-store product literature for customers as well as pharmacists will be made available from CardioComm Solutions in the participating stores. In promoting the launch of the HeartCheck™ ECG PEN, Rexall will promote the device within the Heart Health section of the Health + Wellness area of Rexall's corporate website. In addition, CardioComm Solutions will list those store locations where product has been received by Rexall stores on the CardioComm Solutions HeartCheck™ Website at www.theheartcheck.com.
The HeartCheck™ ECG PEN is approved by Health Canada and the FDA for OTC sales and represents the newest Class II medical device approved for every day home-use in the past 40 years. Its availability represents a groundbreaking advancement that enables progressive pharmacies to offer their clients the opportunity for personalized, in-home heart health monitoring. To the concerned or motivated consumer, the HeartCheck™ ECG PEN will allow them to monitor their heart right at the time they experience difficult to capture or unpredictable symptoms such as racing heart rates, palpitations, dizziness or irregular heartbeats. ECG recordings can be saved and shared with the person's health care provider, or sent to the Company's SMART Monitoring ECG service for review, interpretation and confirmation of the presence of a potential cardiac arrhythmia within 30 minutes.
Intended not only for those actively interested in taking control in maintaining their health, the HeartCheck™ PEN is also for those living with chronic conditions such as hypertension, diabetes, congestive heart disease and may help to identify the presence of atrial fibrillation (AF) and track for signs for risk of sudden cardiac death such as prolonged QRS duration and QT intervals. AF is the most common arrhythmia in developed countries and is associated with a doubling of risk for dementia, a tripling of risk for heart failure, and a 40% to 90% increased risk for overall mortality, according to the Framingham Heart Study. Individuals with atrial fibrillation also have a very high risk of stroke that is 3 to 5 times greater than those without AF according to the Canadian Heart and Stroke Foundation.
The HeartCheck™ PEN introduction into Rexall marks another important milestone in CardioComm Solution's efforts to expand sales throughout Canada. It comes at a time when the provision of managed healthcare in Canada is moving away from traditionally exclusive healthcare providers such as hospitals and when informed consumers are increasingly taking charge of managing their own health. This paradigm shift is one that pharmacies and pharmacists are playing an active role in. Through the introduction of qualified medical devices such as the HeartCheck™ ECG PEN, this continuing shift will serve to relieve some of the current pressures on a heavily burdened Canadian Health Care system. The HeartCheck™ ECG PEN device and GEMS™ Home software will specifically enable consumers to be proactive in managing an important aspect of their health that previously was not possible without a visit to a physician or medical testing laboratory.
CardioComm Solutions will provide further updates on the HeartCheck™ Program and participating pharmacy locations at the www.theheartcheck.com website.
download pdf 
CardioComm Solutions' patented and proprietary
technology is used in products for recording,
viewing, analyzing and storing
electrocardiograms (ECGs) for diagnosis and
management of cardiac patients. Products
are sold worldwide through a combination of an
external distribution network and a North
American-based sales team. The Company has
earned the ISO 13485 certification, is HPB
approved, HIPAA compliant, and has received FDA
market clearance for its software devices.
CardioComm Solutions is headquartered in
Toronto, Canada, with offices in Victoria,
B.C.
FOR FURTHER
INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425
investorrelations@cardiocommsolutions.com
www.cardiocommsolutions.com
Forward-looking
statements
This release may contain certain forward-looking
statements and forward looking information with
respect to the financial condition, results of
operations and business of CardioComm Solutions
and certain of the plans and objectives of
CardioComm Solutions with respect to these
items. Such statements and information reflect
management's current beliefs and are based on
information currently available to management.
By their nature, forward-looking statements and
forward-looking information involve risk and
uncertainty because they relate to events and
depend on circumstances that will occur in the
future and there are many factors that could
cause actual results and developments to differ
materially from those expressed or implied by
these forward-looking statements and
forward-looking information.
In evaluating these statements, readers should:
specifically consider risks discussed under the
heading "Risk Factors" in the Company's Annual
Information Form, available at www.sedar.com;
not to place undue reliance on forward-looking
statements and forward-looking information; be
aware. the Company does not assume any
obligation to update the forward-looking
statements and forward-looking information
contained in this Annual Information Form other
than as required by applicable laws (including
without limitation Section 5.8(2) of National
Instrument 51-102 (Continuous Disclosure
Obligations).
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in
policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of
this release.
|
